Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807)

Oncology

Volumn 66, Issue 2, 2004, Pages 94-100

  Yamada, Kouzo ^a   Ikehara, Mizuki ^a   Tanaka, Gaku ^a   Nomura, Ikuo ^a   Oshita, Fumihiro ^a   Noda, Kazumasa ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

G CSF; Irinotecan; Non small cell lung cancer; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; IRINOTECAN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; DYSPNEA; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; LIVER INJURY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PNEUMONIA; TREATMENT OUTCOME;

EID: 2342489875     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077434     Document Type: Article

References (27)

1. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB: 122 randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 1998;16:2459-2465.
2. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH: Phase III study of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122-130.
3. Geogoulias V, Papadakis E, Alexoupoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I, Greek Oncology Cooperative Group (GOCG) for Lung Cancer: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicenter trial. Lancet 2001;357:1478-1483.
4. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-1229.
5. Sekine I, Nishiwaki Y, Watanabe K, Yoneda S, Saijo N, East Japan Paclitaxel Study Group: Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small-cell lung cancer. Clin Cancer Res 1996;2:941-945.
6. Bissery MC, Vrignaud P, Lavelle F: In vivo evaluation of the docetaxel-irinotecan combination. Proc Am Assoc Cancer Res 1996;37:378.
7. Chou T-C, Motzer RJ, Tong Y, Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-1524.
8. Madden T, Newman RA, Antoun G, Johansen MJ, Ali-Osman F: Low level taxan exposure increases the activity of topoisomerase I targeted agents. Proc Am Assoc Cancer Res 1998;39:527.
9. Pei XH, Nakanishi Y, Takayama K, Bai F, Kawasaki M, Tsuruta N, Mizuno K, Hara N: Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs 1997;8:231-237.
10. Fukuda M, Nishio K, Shiraishi J, Shinkai T, Eguchi K, Tamura T, Ohe Y, Oshita F, Yamamoto N, Kasai T, Kurata T, Ando M, Nagashima S, Oka M, Saijo N: Effects of combinations of CPT-11, paclitaxel and other anticancer agents on human small-cell lung cancer cells. Cell Pharmacol 1996;3:1-6.
11. Akerly W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998;16:153-158.
12. Oshita F, Yamada K, Nomura I, Tanaka G, Ikehara M, Noda K: Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer. Am J Clin Oncol 2000;23:278-282.
13. Fukuoka M, Nagao K, Ohhashi H, Niitani H: Impact of irinotecan (CPT-11) and cisplatin (CDDP) on survival in previously untreated metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000;19:495a.
14. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, World Health Organization, 1979.
15. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, Narabayashi M, Fukutomi T, Kondo H, Shimoyama M, Suemasu K: Toxicity grading criteria of the Japan Clinical Oncology Group. Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993;23:250-257.
16. Masuda N, Fukuoka M, Negoro S, Takada Y, Sugiura T, Ohashi Y, Ariyoshi Y, Niitani H: Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study. The CPT-11 Lung Cancer Study Group West. Proc Am Soc Clin Oncol 1999;18:495a.
17. Niho S, Nagao K, Nishiwaki Y, Yokoyama A, Saijo N, Ohashi Y, Niitani H: Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small-cell lung cancer (NSCLC). CPT-11 Lung Cancer Study Group. Proc Am Soc Clin Oncol 1999;18:492a.
18. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
19. Yamamoto N, Negoro S, Chikazawa H, Shimizu T, Fukuoka M: Pharmacokinetic interaction of the combination of paclitaxel and irinotecan in vivo and clinical study. Proc Am Soc Clin Oncol 1999;18:187a.
20. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC: Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 1991;9:1692-1703.
21. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN: Sequence-dependent alternation of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996;14:2713-2721.
22. Kennedy MJ, Zahurak ML, Donehower RC, Noe DA, Sartorius S, Chen TL, Rowinsky EK: Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 1996;14:783-791.
23. Faucette S, Shord S, Pescatore S, Hawke R, McCune J, Gillenwater H, Socinski M, Lindley C: Paclitaxel affects gemcitabine pharmacokinetics in patients with non-small-cell lung cancer. Proc Am Soc Clin Oncol 2001;20:93a.
24. Saltz L, Kanowitz J, Kemeny NE, Schaaf L, Sprigges D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leukovorin in patients with advanced solid tumors. J Clin Oncol 1996;14:2959-2967.
25. Masuda N, Fukuoka M, Kudoh S, Kusunoki K, Matsui K, Takifuji N, Nakagawa K, Tamanaoi M, Nitta T, Hirashima T, Negoro S, Takada M: Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993;68:777-782.
26. Komuro Y, Udagawa Y, Susumu N, Aoki D, Kubota T, Nozawa S: Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin. Jpn J Cancer Res 2001;92:1242-1250.
27. Murren JR, Peccerillo K, DiStasio SA, Li X, Leffert JJ, Pizzorno G, Burtness BA, McKeon A, Cheng YC: Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemother Pharmacol 2000;46:43-50.